December 2, 2024 01:34 PM EST
Pharma
FDA+

J&J looks to ex­pand Trem­fya in two pe­di­atric in­di­ca­tions

Nicole DeFeudis

Editor

John­son & John­son has filed for two new pe­di­atric in­di­ca­tions as it looks to po­si­tion its block­buster im­munother­a­py Trem­fya as a fol­low-on to its megablock­buster …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Novo­cure says elec­tric field ther­a­py ex­tends life for pan­cre­at­ic can­cer pa­tients by two months

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

Ole­ma, No­var­tis ink an­oth­er agree­ment, this time for a late-stage breast can­cer tri­al

A service from the Financial Times